University Health Network

Neuralink receives approval for first clinical trial in Canada to assess safety and functionality of brain chip enabling paralyzed individuals to control digital devices with thoughts. The trial will be conducted at Toronto's University Health Network hospital. Neuralink has already implanted the device in two U.S. patients, with positive results.

Neuralink, Elon Musk's BCI startup, received Health Canada approval for its first Canadian clinical trial, focusing on safety and functionality of its implant for quadriplegics. The trial mirrors U.S. efforts, with the University Health Network in Toronto selected for neurosurgical procedures. Neuralink's U.S. trial began in 2024, with two patients implanted, showing promising results. The company has faced controversy over animal testing, with over 1,500 animals dying since 2018.

Toronto Western Hospital, part of Canada’s University Health Network, will be the first non-U.S. site for a Neuralink Corp. device trial. Neuralink, Elon Musk’s brain-implant company, received approval from Health Canada for clinical trials in Canada, with recruitment now open for patients with Quadriplegia due to ALS or spinal cord injury.

Neuralink, founded by Elon Musk, received approval from Health Canada for its first clinical trial in Toronto Western Hospital. The trial, exclusive to Canada, recruits quadriplegic patients with conditions like ALS. This marks Neuralink's expansion into clinical trials outside the U.S. and U.K., with a long-term goal of treating various medical conditions, including blindness and memory augmentation.

Perioperative pembrolizumab with preoperative radiation therapy and surgery improved disease-free survival in stage III soft-tissue sarcoma patients, according to a phase II trial (SU2C-SARC032) in The Lancet. The study involved 127 patients with grade 2 or 3, stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma. Disease-free survival at 2 years was 67% in the pembrolizumab group vs 52% in the control group, with higher grade ≥ 3 adverse events in the pembrolizumab group.

Pembrolizumab added to standard care for advanced limb soft tissue sarcoma significantly improved disease-free survival in the SU2C-SARC032 trial, led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre, published in The Lancet.

Arch Biopartners' phase II trial for LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI), has begun patient recruitment and dosing in Canada. The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery. LSALT peptide, Arch Biopartners' lead drug candidate, targets the dipeptidase-1 (DPEP1) pathway to prevent ischemia-reperfusion injury.

Arch Biopartners Inc. announces the start of patient recruitment and dosing in Canada for the Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The University of Calgary has already dosed the first patient, while Toronto General Hospital and St. Michael's Hospital are finalizing approvals. The trial aims to evaluate the percentage of subjects with AKI within seven days post-surgery, using a randomized, double-blind, placebo-controlled approach with a target of 240 patients.

Arch Biopartners Inc. announced the start of patient recruitment and dosing in Canada for its Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with AKI within seven days following on-pump cardiac surgery. The first patient has been dosed at the University of Calgary, with additional sites in Toronto awaiting final approvals.